Abstract:OBJECTIVE To study the reactivation of retinoic acid receptor beta (RARbeta) expression in myeloid leukemia cells by a combination of all-trans retinoic acid (ATRA) with a DNA demethylating agent, decitabine (DAC), and valproic acid (VPA, a histone deacetylase inhibitor),and their effects on cell differentiation and proliferation. METHODS Human myeloid leukemia cells of the line U937 were cultured and treated with all-trans retinoic acid (ATRA), DAC, and VPA. 72 h later cell differentiation test, cloning formation test, and chromatin immunoprecipitation test were performed. Bone marrow specimens were collected from 56 patients with acute myeloblastic leukemia (AML) were cultured and treated with and 10 bone marrow specimens were used as controls. Methylation of RARbeta promoter was detected with methylation specific polymerase chain reaction (MSP) after bisulfite treatment. Relative levels of RARbeta mRNA were assessed with real time quantitative PCR assay. Flow cytometry assay was used to detect the myeloid differentiation marker CD11b in U937 cells. Chromatin immuno-precipitation assay (ChIP) was used to analyze the acetylated histone 3 bound to the retinoic acid response element (RARE) at the promoter region of RARbeta. RESULTS Methylation of RARbeta was positive in 36 of the 56 (64.3%) AML patients and the U937 myeloid leukemia cells, however, was negative in the marrow mononuclear cells from the 10 healthy donors. The expression of RARbeta in U937 cells was up-regulated after treatment with ATRA (1 micromol/L) plus DAC (1 micromol/L) or VPA (0.5 mmol/L) for 72 hours, especially when the three drugs were used together. ChIP assay showed that the acetylated histone 3 bound to the RARE promoter region was increased after the cells were exposed to ATRA plus DAC/VPA. The data indicated that the reactivated expression of RARbeta might be secondary to the drug-induced histone acetylation as well as DNA demethylation. Treatment of U937 cells with ATRA and DAC/VPA also resulted in increased myeloid differentiation (CD11b expression) and decreased plating efficiency. CONCLUSION The repressed expression of RARbeta in myeloid leukemia cells is closely related to both DNA hypermethylation and histone deacetylation, and a combination of ATRA with epigenetic modulators can be beneficial in the treatment of myeloid malignancies.

Expression of histone deacetylase 3 in acute leukemic cell lines

Expression and Regulation Network of HDAC3 in Acute Myeloid Leukemia and the Implication for Targeted Therapy Based on Multidataset Data Mining

ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias

Expression of DcR3 Mrna in Leukemia Cells and Its Significance

Targeting HDAC3 to Overcome the Resistance to ATRA or Arsenic in Acute Promyelocytic Leukemia Through Ubiquitination and Degradation of PML-RARα

Re-Evaluation of Various Molecular Targets Located on Cd34(+)Cd38(-)Lin(-) Leukemia Stem Cells and Other Cell Subsets in Pediatric Acute Myeloid Leukemia

Comprehensive analysis of ECHDC3 as a potential biomarker and therapeutic target for acute myeloid leukemia: Bioinformatic analysis and experimental verification

Expression of Rho GTPase Family Member RhoA and CDC42 Protein in Patients with Acute Leukemia

Expression of human Kruppel-like factor 3 in peripheral blood as a promising biomarker for acute leukemia

HDAC1 and Klf4 interplay critically regulates human myeloid leukemia cell proliferation

[The Expression of DNA Methyltransferase DNMT1, 3A and 3B in Acute Leukemia and Myelodysplastic Syndrome].

Study On the Expression of 14-3-3ζ in Acute Myeloid Leukemic Cell Lines

Expression of Β1,3-N-acetylglucosaminyltransferases During Differentiation of Human Acute Myeloid Leukemia Cells

Targeting HDAC3, a New Partner Protein of AKT in the Reversal of Chemoresistance in Acute Myeloid Leukemia Via DNA Damage Response.

Identification of Histone Deacetylase 3 As a Biomarker for Tumor Recurrence Following Liver Transplantation in HBV-associated Hepatocellular Carcinoma.

High Expression of RhoBTB3 Predicts Favorable Chemothrapy Outcomes in non-M3 Acute Myeloid Leukemia

Histone deacetylase 3 gene in hematopoietic stem cells promotes mouse lymphogenesis

Differential Mrna Expression Levels Of Human Histone-Modifying Enzymes In Normal Karyotype B Cell Pediatric Acute Lymphoblastic Leukemia

[Epigenetic Regulation of Expression of Retinoic Acid Receptor Beta Gene in Leukemia Cell].

Gene expression profiling of the DNMT3A R882 mutation in acute leukemia.